47c020f3b1f60842…

{
  "id": "NCT00000178",
  "type": "Study",
  "data": {
    "briefSummary": "This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.",
    "completionDate": null,
    "conditions": [
      "Alzheimer Disease"
    ],
    "enrollmentCount": null,
    "enrollmentType": null,
    "nctId": "NCT00000178",
    "phase": "PHASE3",
    "sponsorId": "national-institute-on-aging-nia",
    "startDate": null,
    "status": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "title": "Multicenter Trial of Prednisone in Alzheimer's Disease",
    "url": "https://clinicaltrials.gov/study/NCT00000178"
  }
}